Tweet this “People living with diabetes are benefiting from our Control-IQ technology across diverse populations and therapeutic backgrounds, which supports our mission to improve the lives of people ...

Studies underscore advances in screening, mental health, health equity, and early intervention in diabetes care. New study examines benefits of continuous glucose monitoring (CGM) in people with type ...

Ingelheim, Germany and Indianapolis, US, 10 June, 2014 – More than 40 presentations including posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of ...

INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th ...

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels ...

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific ...

JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, ...

Credit: Getty Images. Worldwide, 2% to 12% of people diagnosed with type 2 diabetes have latent autoimmune diabetes in adulthood (LADA). A 41-year-old Hispanic woman presents to her worksite clinic ...